Cara Therapeutics, Inc. 0HTC.L Stock
Cara Therapeutics, Inc. Price Chart
Cara Therapeutics, Inc. 0HTC.L Financial and Trading Overview
Cara Therapeutics, Inc. stock price | 0.79 USD |
Previous Close | 3.52 USD |
Open | 0 USD |
Bid | 0 USD x N/A |
Ask | 0 USD x N/A |
Day's Range | 0 - 0 USD |
52 Week Range | 0 - 12.86 USD |
Volume | 1.37K USD |
Avg. Volume | 1.59K USD |
Market Cap | 1.26M USD |
Beta (5Y Monthly) | 0.861619 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.8 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0HTC.L Valuation Measures
Enterprise Value | 57.71M USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.029153462 |
Price/Book (mrq) | 1.2481629 |
Enterprise Value/Revenue | 1.335 |
Enterprise Value/EBITDA | -0.663 |
Trading Information
Cara Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 0.861619 |
52-Week Change | -59.60% |
S&P500 52-Week Change | 20.43% |
52 Week High | 12.86 USD |
52 Week Low | 0 USD |
50-Day Moving Average | 4.11 USD |
200-Day Moving Average | 7.49 USD |
0HTC.L Share Statistics
Avg. Volume (3 month) | 1.59K USD |
Avg. Daily Volume (10-Days) | 734 USD |
Shares Outstanding | 39.45M |
Float | 45.25M |
Short Ratio | N/A |
% Held by Insiders | 14.36% |
% Held by Institutions | 65.33% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -195.15% |
Operating Margin (ttm) | -201.82% |
Gross Margin | -134.90% |
EBITDA Margin | -201.26% |
Management Effectiveness
Return on Assets (ttm) | -28.92% |
Return on Equity (ttm) | -49.53% |
Income Statement
Revenue (ttm) | 43.24M USD |
Revenue Per Share (ttm) | 0.81 USD |
Quarterly Revenue Growth (yoy) | 28.69% |
Gross Profit (ttm) | -56141000 USD |
EBITDA | -87031000 USD |
Net Income Avi to Common (ttm) | -84390000 USD |
Diluted EPS (ttm) | -1.8 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 114.28M USD |
Total Cash Per Share (mrq) | 2.12 USD |
Total Debt (mrq) | 1.46M USD |
Total Debt/Equity (mrq) | 1.07 USD |
Current Ratio (mrq) | 8.554 |
Book Value Per Share (mrq) | 2.531 |
Cash Flow Statement
Operating Cash Flow (ttm) | -87823000 USD |
Levered Free Cash Flow (ttm) | -56472248 USD |
Profile of Cara Therapeutics, Inc.
Country | United Kingdom |
State | CT |
City | Stamford |
Address | 4 Stamford Plaza |
ZIP | 06902 |
Phone | 203 406 3700 |
Website | https://www.caratherapeutics.com |
Industry | |
Sector(s) | |
Full Time Employees | 106 |
Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.
Q&A For Cara Therapeutics, Inc. Stock
What is a current 0HTC.L stock price?
Cara Therapeutics, Inc. 0HTC.L stock price today per share is 0.79 USD.
How to purchase Cara Therapeutics, Inc. stock?
You can buy 0HTC.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cara Therapeutics, Inc.?
The stock symbol or ticker of Cara Therapeutics, Inc. is 0HTC.L.
How many shares does Cara Therapeutics, Inc. have in circulation?
The max supply of Cara Therapeutics, Inc. shares is 399.05K.
What is Cara Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Cara Therapeutics, Inc. PE Ratio is now.
What was Cara Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Cara Therapeutics, Inc. EPS is -1.8 USD over the trailing 12 months.